Chang‐Ik Choi

1.7k total citations
70 papers, 1.4k citations indexed

About

Chang‐Ik Choi is a scholar working on Pharmacology, Pharmacology and Oncology. According to data from OpenAlex, Chang‐Ik Choi has authored 70 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pharmacology, 23 papers in Pharmacology and 22 papers in Oncology. Recurrent topics in Chang‐Ik Choi's work include Pharmacogenetics and Drug Metabolism (33 papers), Drug Transport and Resistance Mechanisms (20 papers) and Analytical Methods in Pharmaceuticals (11 papers). Chang‐Ik Choi is often cited by papers focused on Pharmacogenetics and Drug Metabolism (33 papers), Drug Transport and Resistance Mechanisms (20 papers) and Analytical Methods in Pharmaceuticals (11 papers). Chang‐Ik Choi collaborates with scholars based in South Korea, United States and Thailand. Chang‐Ik Choi's co-authors include Sung Ho Lim, Seok‐Yong Lee, Choon‐Gon Jang, Jung‐Woo Bae, Ki Hyun Kim, Hye-In Lee, Yun Jeong Lee, Seoung Rak Lee, Young‐Hoon Kim and Jae Sik Yu and has published in prestigious journals such as International Journal of Molecular Sciences, Molecules and Nutrients.

In The Last Decade

Chang‐Ik Choi

66 papers receiving 1.3k citations

Peers

Chang‐Ik Choi

PHARM

ONCOL

EDM

Kwang‐il Kwon South Korea

Su‐Lan Hsiu Taiwan

Yueming Ma China

Dongsheng Ouyang China

Hsien‐Tsung Yao Taiwan

Jim Fang Canada

Bidya Dhar Sahu India

Noriko Ohashi Japan

N. Nalini India

Peiwu Geng China

Kwang‐il Kwon South Korea

Chang‐Ik Choi

201 ×0.4

PHARM

196 ×0.6

PHARM

454 ×1.5

228 ×0.9

ONCOL

137 ×0.6

EDM

Citations per year, relative to Chang‐Ik Choi Chang‐Ik Choi (= 1×) peers Kwang‐il Kwon

Countries citing papers authored by Chang‐Ik Choi

Since Specialization

Citations

This map shows the geographic impact of Chang‐Ik Choi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chang‐Ik Choi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chang‐Ik Choi more than expected).

Fields of papers citing papers by Chang‐Ik Choi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chang‐Ik Choi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chang‐Ik Choi. The network helps show where Chang‐Ik Choi may publish in the future.

Co-authorship network of co-authors of Chang‐Ik Choi

This figure shows the co-authorship network connecting the top 25 collaborators of Chang‐Ik Choi. A scholar is included among the top collaborators of Chang‐Ik Choi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chang‐Ik Choi. Chang‐Ik Choi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Hye-Jung, Sangho Lee, Choon‐Gon Jang, et al.. (2025). Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19. Archives of Pharmacal Research. 48(3). 234–250.

Jang, Choon‐Gon, et al.. (2024). Effects of fluconazole on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes. Archives of Pharmacal Research. 48(3). 224–233.

Lim, Sung Ho, et al.. (2023). Effect of Betanin, the Major Pigment of Red Beetroot (Beta vulgaris L.), on the Activity of Recombinant Human Cytochrome P450 Enzymes. Pharmaceuticals. 16(9). 1224–1224. 3 indexed citations

Choi, Chang‐Ik, et al.. (2023). Black Goji Berry (Lycium ruthenicum Murray): A Review of Its Pharmacological Activity. Nutrients. 15(19). 4181–4181. 21 indexed citations

Jang, Choon‐Gon, et al.. (2023). Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism. Archives of Pharmacal Research. 47(2). 95–110. 5 indexed citations

Jang, Choon‐Gon, et al.. (2023). Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects. Archives of Pharmacal Research. 46(5). 438–447. 8 indexed citations

Park, Hye-Jung, Yun Jeong Lee, Chang‐Ik Choi, et al.. (2022). Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes. Archives of Pharmacal Research. 45(8). 584–595. 11 indexed citations

Bae, Jung‐Woo, et al.. (2020). Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Archives of Pharmacal Research. 43(11). 1207–1213. 29 indexed citations

Lee, Yun Jeong, et al.. (2020). ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan. Archives of Pharmacal Research. 43(11). 1187–1196. 26 indexed citations

10.

Kim, Mi‐Jung, Young‐Hoon Kim, Se‐Hyung Kim, et al.. (2018). Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites. Archives of Pharmacal Research. 41(3). 347–353. 21 indexed citations

11.

Kim, Se‐Hyung, Do-Hoon Kim, Young‐Hoon Kim, et al.. (2016). Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Archives of Pharmacal Research. 40(3). 382–390. 43 indexed citations

12.

Lee, Hye-In, Jung‐Woo Bae, Chang‐Ik Choi, et al.. (2013). Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. Pharmacogenetics and Genomics. 24(2). 113–117. 23 indexed citations

13.

Bae, Jung‐Woo, Chang‐Ik Choi, Hye-In Lee, et al.. (2012). Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. International Journal of Clinical Pharmacology and Therapeutics. 50(9). 683–689. 21 indexed citations

14.

Choi, Chang‐Ik, Hye-In Lee, Jung‐Woo Bae, et al.. (2012). Determination of tamsulosin in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Journal of Chromatography B. 909. 65–69. 16 indexed citations

15.

Bae, Jung‐Woo, et al.. (2011). Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacologica Sinica. 32(10). 1303–1308. 40 indexed citations

16.

Choi, Chang‐Ik, Mi‐Jeong Kim, Choon‐Gon Jang, et al.. (2011). Effects of the CYP2C9*1/*13 Genotype on the Pharmacokinetics of Lornoxicam. Basic & Clinical Pharmacology & Toxicology. 109(6). 476–480. 25 indexed citations

17.

Choi, Chang‐Ik, Jung‐Woo Bae, Hye-In Lee, et al.. (2011). Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Journal of Chromatography B. 885-886. 103–108. 14 indexed citations

18.

Bae, Jung‐Woo, et al.. (2010). Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. European Journal of Clinical Pharmacology. 67(1). 39–45. 17 indexed citations

19.

Bae, Jung‐Woo, Ji Hong Kim, Chang‐Ik Choi, et al.. (2009). Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Archives of Pharmacal Research. 32(2). 269–273. 14 indexed citations

20.

Lee, Yongjin, Chang‐Ik Choi, Sang-Woo Lee, et al.. (2007). Increases in Doxorubicin Sensitivity and Radioiodide Uptake by Transfecting shMDR and Sodium/Iodide Symporter Gene in Cancer Cells Expressing Multidrug Resistance. Nuclear Medicine and Molecular Imaging. 41(3). 209–217. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact